IN8bio, Inc. (INAB)

NASDAQ: INAB · IEX Real-Time Price · USD
3.87 -0.18 (-4.44%)
Jan 18, 2022 4:00 PM EST - Market closed
Market Cap72.58M
Revenue (ttm)n/a
Net Income (ttm)-13.25M
Shares Out18.75M
EPS (ttm)-1.94
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,515
Open3.61
Previous Close4.05
Day's Range3.61 - 4.05
52-Week Range3.57 - 10.32
Betan/a
AnalystsStrong Buy
Price Target15.50 (+300.5%)
Earnings Daten/a

About INAB

IN8bio is a clinical-stage biotechnology company focused on developing innovative therapies for the treatment of cancers, including solid tumors, by employing allogeneic, autologous and genetically modified gamma-delta T cells. Gamma-delta T cells are naturally occurring cells in the human immune system that recognize and kill cancerous cells, while possessing a tumor recognition mechanism that protects healthy tissue. Gamma-delta T cells embody properties of both the innate and adaptive immune systems, which allows for them to serve as a funct...

IndustryBiotechnology
IPO DateJul 30, 2021
CEOWilliam Ho
Employees13
Stock ExchangeNASDAQ
Ticker SymbolINAB
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 2 analysts, the average rating for IN8bio stock is "Strong Buy." The 12-month stock price forecast is 15.50, which is an increase of 300.52% from the latest price.

Price Target
$15.50
(300.52% upside)
Analyst Consensus: Strong Buy

News

IN8bio to Present at Upcoming January Investor Conferences

NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ut...

1 week ago - GlobeNewsWire

IN8bio Announces Clinical Updates from the Phase 1 Clinical Trial of its Genetically Modified Gamma-Delta T Cell Ther...

NEW YORK, Jan. 06, 2022 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ut...

1 week ago - GlobeNewsWire

IN8bio Stock Jumps After An Update From Leukemia Trial

IN8bio Inc (NASDAQ: INAB) has provided an update on the Phase 1 clinical trial of INB-100, a donor-derived gamma-delta T cell therapy for leukemia patients undergoing haploidentical hematopoietic stem c...

1 month ago - Benzinga

IN8bio Provides Update from the Ongoing Phase 1 Clinical Trial of its Allogeneic Gamma-Delta T Cell Therapy in Leukem...

NEW YORK, Dec. 16, 2021 (GLOBE NEWSWIRE) --  IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies u...

1 month ago - GlobeNewsWire

IN8bio Promotes Kate Rochlin, Ph.D. to Chief Operating Officer

NEW YORK, Dec. 09, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ut...

1 month ago - GlobeNewsWire

IN8bio Appoints Trishna Goswami, M.D. as Chief Medical Officer

NEW YORK, Nov. 16, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ut...

2 months ago - GlobeNewsWire

IN8bio to Present Preclinical Data on the Potential for Gamma-Delta T-cell Therapy Combinations with PARP and Checkpo...

NEW YORK, Nov. 11, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...

2 months ago - GlobeNewsWire

IN8bio Reports Third Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Nov. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T cell therapies ut...

2 months ago - GlobeNewsWire

IN8bio to Present at Scientific Conferences in November: PEGS Europe, SITC and SNO

NEW YORK, Nov. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...

2 months ago - GlobeNewsWire

IN8bio's Announces Peer-Reviewed Publication of Preclinical Results Using Proprietary MGMT-modified Gamma-Delta T Cel...

Concurrent dosing of MGMT-modified gamma-delta T cells with Temozolomide (TMZ) demonstrated a significant survival benefit across multiple models of high-grade glioma

2 months ago - GlobeNewsWire

IN8bio to Present at BioFuture 2021 and Advanced Therapies Congress & Expo 2021

NEW YORK, Oct. 04, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...

3 months ago - GlobeNewsWire

IN8bio Reports Second Quarter 2021 Financial Results and Provides Corporate Update

NEW YORK, Sept. 10, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies u...

4 months ago - GlobeNewsWire

IN8bio to Present at the NewYorkBIO Virtual Breakfast Series and H.C. Wainwright 23rd Annual Global Investment Confer...

NEW YORK, Aug. 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery and development of innovative gamma-delta T-cell therapies ut...

4 months ago - GlobeNewsWire

IN8bio Completes Dosing of First Cohort in Phase 1 Clinical Trial with Allogeneic Gamma Delta T-Cell Therapy in Leuke...

The first cohort has completed dosing with IN8bio's donor derived allogeneic gamma delta T-cell product candidate, INB-100, with no severe adverse infusion reactions or dose limiting toxicities (DLTs) o...

5 months ago - GlobeNewsWire

IN8bio Announces Pricing of Initial Public Offering

NEW YORK, July 30, 2021 (GLOBE NEWSWIRE) -- IN8bio, Inc. (Nasdaq: INAB), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of gamma-delta T cell ther...

5 months ago - GlobeNewsWire